DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
NCT ID: NCT05254119
Last Updated: 2024-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
6000 participants
OBSERVATIONAL
2021-12-01
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
NCT02622581
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
NCT05320458
Assessment of Functional Capacity, Pain, Cognitive and Respiratory Functions in Lung Cancer Survivors
NCT04431921
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197
Molecular Profiling in Small Cell Lung Cancer
NCT03162705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written informed consent no later than six weeks after start of first-line treatment
3. Age ≥ 18 years
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahmut Gumus
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmut Gumus
Board Member of Oncological Clinical Research Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adana Başkent University Hospital
Adana, , Turkey (Türkiye)
Adana City Training and Research Hospital
Adana, , Turkey (Türkiye)
Ankara City Hospital (1)
Ankara, , Turkey (Türkiye)
Ankara City Hospital (2)
Ankara, , Turkey (Türkiye)
Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara, , Turkey (Türkiye)
Ankara Gülhane Traning and Research Hospital
Ankara, , Turkey (Türkiye)
Ankara Liv Hospital
Ankara, , Turkey (Türkiye)
Ankara Memorial Hospital
Ankara, , Turkey (Türkiye)
Dıskapı Yıldırım Beyazid Training and Research Hospital
Ankara, , Turkey (Türkiye)
Antalya Training and Research Hospital
Antalya, , Turkey (Türkiye)
Bursa Uludağ University Hospital
Bursa, , Turkey (Türkiye)
Canakkale 18 Mart University Medicine Faculty Hopsital
Çanakkale, , Turkey (Türkiye)
Dicle University Medicine Faculty Hospital
Diyarbakır, , Turkey (Türkiye)
Trakya University Medicine Faculty Hospital
Edirne, , Turkey (Türkiye)
Erzurum Atatürk University Medicine Faculty Hospital
Erzurum, , Turkey (Türkiye)
Gaziantep University Medicine Faculty Hospital
Gaziantep, , Turkey (Türkiye)
Acibadem University Hospital
Istanbul, , Turkey (Türkiye)
Akdeniz University Medicine Faculty Hospital
Istanbul, , Turkey (Türkiye)
Bakırköy Dr. Sadi Konuk Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Bezmialem Vakıf University Hospital
Istanbul, , Turkey (Türkiye)
Istanbul Medeniyet University
Istanbul, , Turkey (Türkiye)
Istanbul Oncology Hospital
Istanbul, , Turkey (Türkiye)
Istanbul Umraniye Training and Research Hsopital
Istanbul, , Turkey (Türkiye)
Istanbul University Cerrahpasa Medicine Faculty Hospital
Istanbul, , Turkey (Türkiye)
Kartal Dr. Lütfi Kırdar Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Marmara University Hospital
Istanbul, , Turkey (Türkiye)
Medipol University Hospital
Istanbul, , Turkey (Türkiye)
Pendik Medical Park Hospital
Istanbul, , Turkey (Türkiye)
Prof.Dr. Cemil Taşcıoğlu City Hospital
Istanbul, , Turkey (Türkiye)
Sureyyapasa Chest Disease Hospital
Istanbul, , Turkey (Türkiye)
Ege University Medicine Fculty Hospital
Izmir, , Turkey (Türkiye)
Izmir Medical Park Hospital
Izmir, , Turkey (Türkiye)
Kocaeli University Hospital
İzmit, , Turkey (Türkiye)
Erciyes Üniversity Medicine Faculty Hospital
Kayseri, , Turkey (Türkiye)
Necmettin Erbakan University Meram Medicine Faculty Hospital
Konya, , Turkey (Türkiye)
Inonu Uniersity Medicine Faculty Hospital
Malatya, , Turkey (Türkiye)
Sakarya University Training and Research Hospital
Sakarya, , Turkey (Türkiye)
Samsun Ondokuz Mayıs University Medicine Faculty Hospital
Samsun, , Turkey (Türkiye)
Karadeniz Technical University Medicine Faculty Hospital
Trabzon, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUNG-RWD-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.